Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.03
EPS est.
$-0.45
EPS surprise
+93.35%
1-day move
-3.12%
PTC Therapeutics reported a smaller-than-expected loss per share, which is a positive surprise for investors. However, the stock fell by 3.12% in reaction, indicating that investors may have been anticipating more robust revenue figures. The lack of revenue reporting and guidance may have contributed to the negative stock movement.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.03 | $-0.44 | +93.35% |
| Revenue | — | $233M | — |
No transcript is on record, and the analysis is based on numerical results only.
PTC Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases. Operating in the health care sector, its work is crucial as it addresses unmet medical needs and aims to improve the quality of life for patients with serious conditions.
Last quarter
In the last quarter, PTC Therapeutics reported an EPS of $-1.67, significantly missing analyst expectations. The stock reacted positively, gaining 1.41% the following day despite the disappointing results.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+154.79%
Avg 1-day reaction
-1.85%
Analysts expect PTC Therapeutics to report a loss of $0.44 per share on revenues of $233 million. Given the company's history of earnings surprises, there is a mix of optimism and caution in the market.
Bull case
If PTC Therapeutics can exceed revenue expectations and demonstrate strong demand for its products, it could lead to a positive reassessment of the company's growth potential.
Bear case
Conversely, if the company fails to meet revenue expectations or shows continued losses, it could raise concerns about its financial health and future viability.
Key metrics to watch
EPS
$-0.44Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$233MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
What will the actual revenue number be compared to the consensus of $233 million?
Revenue is critical for assessing the company's growth trajectory and market demand for its products.
Q2
How does management plan to address the significant EPS loss of $-0.44?
Investors will be keen to hear about strategies to improve profitability and manage costs moving forward.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The Street may be underestimating the potential for revenue growth due to recent product launches that have not yet fully impacted sales figures.
Supporting evidence
The company's historical EPS surprise rate is 88%, suggesting a tendency to outperform expectations.
Options are pricing in a larger move than the stock has historically experienced, indicating potential for a surprise.
Recent insider selling may signal a lack of confidence in the near-term outlook, which could be misinterpreted by the market.
Key risk
If revenue comes in below $164 million, it could invalidate the optimistic growth narrative.
Pre-commit to what would confirm each case.
The market is weighing the potential for growth against the backdrop of recent earnings surprises and historical performance.
Bull confirmed if
Revenue exceeding $233 million would indicate strong demand and growth potential.
Bear confirmed if
Revenue significantly below $164 million could raise serious concerns about the company's future.
What the market is pricing for the move.
Implied Move
±13.45%
Historical Avg
±2.6%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±13.5% while PTCT has averaged ±2.6% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
39.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.9%, with a raw directional average of +0.3% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$914,710.74
14,073 sh
2 insiders
Net
$914,710.74
Net selling
Most Active Insiders· 3 open-market trades
$132,790.74
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
122.83%
of float
Insider
7.31%
of float
Holders
521
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,964,554 sh · $883.0M
16.73%
7.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If PTC Therapeutics beats expectations, history suggests the stock could see a positive reaction, potentially around a 2.36% increase.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss on earnings could lead to a decline, with historical patterns indicating an average drop of around 1.41%.
The lines on the call that would change the story.
$781,920.00
Net selling
Recent Transactions
Sep 30, 2026 · @ $65.16
12,000 sh
$781,920.00
Oct 5, 2026 · @ $64.03
1,638 sh
$104,881.14
Oct 6, 2026 · @ $64.16
435 sh
$27,909.60
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
RTW Investments LP
7,746,415 sh · $489.8M
9.28%
Flat
Jupiter Topco LLC
7,236,402 sh · $457.6M
8.67%
100.0%
Vanguard Portfolio Management LLC
4,928,111 sh · $311.6M
5.90%
2.6%
State Street Corporation
4,598,952 sh · $290.8M
5.51%
5.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.